Skip to main content
Premium Trial:

Request an Annual Quote

Sygnis Raises $6.2M in Private Equity

NEW YORK (GenomeWeb) – Sygnis today announced that it has raised €5 million ($6.2 million) in a rights offering to German and international institutional investors.

The company said the subscription ratio in the offering was 13:3, meaning 13 existing shares entitled the shareholder to subscribe for three new shares in the firm. The subscription price was €2 per share. Shares that were not subscribed in the rights offering were offered to select German and international institutional investors at the same price.

The firm said in a statement that it expects the TruePrime Single Cell WGA kit, its first proprietary product, to launch in January 2015 and it has signed a distribution deal for the product with BioCat.

"The transaction provides the company with the financial flexibility needed to expand its proprietary portfolio of exciting new products and to meet the next milestones in our corporate and commercial development plan," Sygnis CEO Pilar de la Heurta said.

Heidelberg, Germany-based Sygnis said it plans to use the proceeds to finance the development and commercialization of its products and for operations.

Sygnis was advised by GBC AG.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.